Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
Andrea Citarella, Angela Scala, Anna Piperno, et al.
Biomolecules (2021) Vol. 11, Iss. 4, pp. 607-607
Open Access | Times Cited: 135

Showing 26-50 of 135 citing articles:

Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors
Shenghua Gao, Letian Song, Tobias Claff, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16902-16917
Closed Access | Times Cited: 25
Exploring new catechin derivatives as SARS-CoV-2 Mpro inhibitors from tea by molecular networking, surface plasma resonance, enzyme inhibition, induced fit docking, and metadynamics simulations
Zi Yang, Wei Wang, Yan Qi, et al.
Computers in Biology and Medicine (2022) Vol. 151, pp. 106288-106288
Open Access | Times Cited: 23
Advances in the discovery of new chemotypes through ultra-large library docking
Felix Potlitz, Andreas Link, Lukas Schulig
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 303-313
Closed Access | Times Cited: 16
Recent Advances on SARS-CoV-2 Mpro Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
(2023)
Open Access | Times Cited: 14
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
Chiranjib Chakraborty, Manojit Bhattacharya, Abdulrahman Alshammari, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 12, pp. 1961-1970
Open Access | Times Cited: 14
Investigation of phytochemicals isolated from selected Saudi medicinal plants as natural inhibitors of SARS CoV-2 main protease: In vitro, molecular docking and simulation analysis
Yousef Alharbi, Wael M. Abdel‐Mageed, Omer A. Basudan, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 5, pp. 102023-102023
Open Access | Times Cited: 5
SARS-CoV-2 Mpro oligomerization as a potential target for therapy
Kinga Lis, Jacek Plewka, Filipe Menezes, et al.
International Journal of Biological Macromolecules (2024) Vol. 267, pp. 131392-131392
Open Access | Times Cited: 5
In-silico investigation of phenolic compounds from leaves of Phillyrea angustifolia L. as a potential inhibitor against the SARS-CoV-2 main protease (Mpro PDB ID:5R83) using a virtual screening method
Ahmed Boufissiou, Mohnad Abdalla, Mohamed Sharaf, et al.
Journal of Saudi Chemical Society (2022) Vol. 26, Iss. 3, pp. 101473-101473
Open Access | Times Cited: 20
A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2
Prakriti Kashyap, Vijay Kumar Bhardwaj, Mahima Chauhan, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 20
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115021-115021
Open Access | Times Cited: 19
Design of Potent Inhibitors Targeting the Main Protease of SARS-CoV-2 Using QSAR Modeling, Molecular Docking, and Molecular Dynamics Simulations
Mehdi Oubahmane, Ismail Hdoufane, Christelle Delaite, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 608-608
Open Access | Times Cited: 11
Insights into SARS-CoV-2 structure: Approaches and action of SARS-CoV-2 main protease inhibitor
Ilma Shakeel, Aaliya Taiyab, Aanchal Rathi, et al.
Elsevier eBooks (2025), pp. 89-117
Closed Access
Azadirachta Indica Phytoconstituents as Novel Inhibitors for Main Proteases of COVID-19: Molecular Dynamics and Simulation Study
Ubaida Hussain, Fatima Gillani, Laiba Gull, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 1, pp. 74-84
Closed Access
Identification of promising SARS-CoV-2 main protease inhibitor through molecular docking, dynamics simulation, and ADMET analysis
Ganesh Sharma, Neeraj Kumar, Chandra Shekhar Sharma, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Molecular imaging of viral pathogenesis and opportunities for the future
Brianna Kelly, Jeanette E. Boudreau, Steven Beyea, et al.
npj Imaging (2025) Vol. 3, Iss. 1
Open Access
Design, synthesis and biological activity of peptidyl β-nitrostyrenes as cysteine protease inhibitors against Leishmania donovani
Sweta Sharma, Mirza Beg, Insha Latief, et al.
RSC Advances (2025) Vol. 15, Iss. 8, pp. 5703-5719
Open Access
Novel Benzosuberone/Indanone‐Linked Thiazoles as Small‐Molecule SARS‐CoV‐2 Main Protease Inhibitors
Thoraya A. Farghaly, Elham N. Bifari, Mariam A. Al‐Sheikh, et al.
Drug Development Research (2025) Vol. 86, Iss. 2
Closed Access
A phycobiliprotein-based reporter assay for the evaluation of SARS-CoV-2 main protease activity
Le Cao, Shuyuan Shi, Chaofeng Zhang, et al.
Virology (2025) Vol. 608, pp. 110540-110540
Closed Access
In silico studies on structural inhibition of SARS-CoV-2 main protease Mpro by major secondary metabolites of Andrographis paniculata and Cinchona officinalis
Moumita Majumdar, Vishal Singh, Tarun Kumar Misra, et al.
Biologia (2022) Vol. 77, Iss. 5, pp. 1373-1389
Open Access | Times Cited: 17
Cleavage of the selective autophagy receptor SQSTM1/p62 by the SARS-CoV-2 main protease NSP5 prevents the autophagic degradation of viral membrane proteins
Yabin Zhang, Shiyan Liu, Qingjia Xu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 17
AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity In Vitro
Luiz Saramago, Marcos V. Santana, Bárbara Figueira Gomes, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 9, pp. 2866-2880
Closed Access | Times Cited: 10
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants
Jimena Pérez‐Vargas, L.J. Worrall, Andrea Olmstead, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 10
Antiviral Effect of 5′-Arylchalcogeno-3-aminothymidine Derivatives in SARS-CoV-2 Infection
Amanda Resende Tucci, Raquel Mello da Rosa, Alice Santos Rosa, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6696-6696
Open Access | Times Cited: 10
Identification of amentoflavone as a potent SARS-CoV-2 M pro inhibitor: a combination of computational studies and in vitro biological evaluation
Prabuddha Bhattacharya, Anirban Mandal
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-19
Closed Access | Times Cited: 3
Novel 1,3-Indanedione-Thiazole Hybrids as Small-Molecule SARS-COV-2 Main Protease Inhibitors With Potential anti-Coronaviral Activity
Thoraya A. Farghaly, Ghada S. Masaret, Hanan Gaber Abdulwahab
Polycyclic aromatic compounds (2024), pp. 1-16
Closed Access | Times Cited: 3

Scroll to top